세계의 항균제 감수성 시험(AST) 시장 : 제품별, 방법별, 유형별, 용도별, 최종 사용자별, 지역별 - 예측(-2029년)

The global antimicrobial susceptibility testingmarket is projected to reach USD 5.68 billion by 2029 from USD 4.45 billion in 2024, growing at a CAGR of 5.0% during the forecast period. Key advantages of the AST market include the fact that it is very crucial in improving patient care through proper identification and timely selection of effective antimicrobial therapy. AST therefore has an added advantage in combating the rise of the antimicrobial resistance problem in providing correct susceptibility profiles that assist appropriate antibiotic usage.

"Consumables to register largest market share in 2022-2029."

The largest share in antimicrobial susceptibility testing (AST) is held by the consumables segment. A significant and ever-increasing amount of critical material is consumed. It comprises culture media, reagents, antibiotic discs, and other materials and can be considered basically necessary for AST procedures. The market share of the consumable is thus added to owing to the growing incidence of infectious diseases and the emergence of antibiotic-resistant pathogens and increasing demand for AST services.

Second, the production of more sophisticated AST technologies will need more technical consumables. Obviously, molecular-based AST methods will require specific nucleic acid extraction kits, PCR reagents, and detection probes. Persistent demand for accurate and effective AST testing creates a sustainable demand for consumables, which further solidifies them as the core of the overall AST market.

"Hospitals & diagnostic centers segment held the largest share of antimicrobial susceptibility testingmarket in 2023, by End-user."

Based on the end-user, the antimicrobial susceptibility testing market is segmented into hospitals & diagnostic laboratories, pharmaceutical and biotechnology companies, research & academic Institutes and clinical research organizations. In the year 2023, the global antimicrobial susceptibility testing market was dominated by hospitals and diagnostic centers. Growth within the number of hospitals and diagnostic centers in the AST market is also derived from increases in the timely and accurate diagnostics needs for managing infectious diseases and fighting against antimicrobial resistance.

.

"Asia Pacific to register highest growth rate in the market during the forecast period."

The Asia Pacific region, and China in particular, is witnessing a very rapid growth in the AST market due to various reasons. The increasing population in this region, allied with increasing incomes and access to better health care, has resulted in more stringent demands for diagnostics services. It is not overstressed in the sense that the ever-growing occurrence of infectious diseases and antimicrobial-resistant pathogens demands utmost importance in attaching real value to accurate AST as the primary basis for guiding proper treatment.

Advances in AST technology, particularly through the development of molecular rapid diagnostics and automated systems, is driving the market.. These speed up the process of AST, give results quicker in turn-around time, have increased efficiency with precise results, which put AST within the reach of healthcare providers. Additionally, the investments done by governments in upgrading the health care infrastructure along with such initiatives have paved a favorable path toward the growth of the market in the country, particularly in China.

A number of drivers were responsible for the upswing, including:

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
• By Designation: C-level-- 10%, Director-level-14%, and Others-76%
• By Region: North America-40%, Europe-30%, Asia Pacific-20%, Latin America- 5%, Middle east and africa- 5%

Prominent players in this market are BioMerieux (France), Becton, Dickinson and company (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Bio-Rad laboratories (US), Bruker (US), Roche diagnostics (Switzerland, Accelerate diagnostics (US), Himedia laboratories (India), Liofilchem s.r.l.(Italy), Alifax s.r.l.(Italy), Creative Diagnostics (US), among others.

Research Coverage

The market is segmented into product, type, method, application, end user, and region. In the report, factors affecting the antimicrobial susceptibility testing market- drivers, restraints, opportunities, and challenges-are described. Opportunities and challenges for stakeholders and the details of leading players' competitive landscape are also highlighted. The report further segments the micro-markets into growth trends, prospects, and contribution to the antimicrobial susceptibility testing market. It forecasts revenue growth from different market segments, focusing on five major geographical regions.

Key Benefits of Buying the Report:

The report is designed to aid new entrants by providing them with detailed data on the antimicrobial susceptibility testing market, thereby allowing them to understand investment opportunities. It provides comprehensive insight into key players as well as smaller ones, thus favoring strong risk assessment and informed investment decisions. Due to precise segmentation-such as by end-users and regions-the report offers focused insights in specific segments of the market. It further outlines the critical trends, challenges, growth drivers, and opportunities that complete the strategic decision-making process with well-rounded analysis.

The report provides the insights on the following pointers:

Analysis of the key drivers, restraints, opportunities, and challenges influencing the rise of the antimicrobial susceptibility testing market. The key drivers of antimicrobial susceptibility testing are an upsurge in infectious diseases and, correspondingly, higher numbers of antibiotic resistance around the world. Growing demand for timely and accurate diagnostic tools that guide effective treatment strategies fuels demand for AST. Technologically, the development of rapid and automated testing systems supports market growth by increasing efficiency and accuracy in tests.

Product Development/Innovation: Insights into emerging technologies, current R&D activities, and recent launches of products and services in the antimicrobial susceptibility testing market.

Market Development: The report further provides in detail the profitable markets by segmenting the antimicrobial susceptibility testing market into various regions

Market Diversification: Detailed insight into new product launches, unexplored markets, recent developments, and investments made in the antimicrobial susceptibility testing market.

Competitive Assessment: Detailed assessment of market share, service offerings leading strategies of key players such as BioMerieux (France), Becton, Dickinson and company (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Bio-Rad laboratories (US), among others.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH DESIGN
  • 2.2.1 SECONDARY RESEARCH
  • 2.2.2 PRIMARY RESEARCH
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key industry insights
    • 2.2.2.3 Breakdown of primaries
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
    • 2.3.1.2 Approach 2: Customer-based market estimation
    • 2.3.1.3 Approach 3: Top-down approach
    • 2.3.1.4 Approach 4: Primary interviews
    • 2.3.1.5 CAGR projections
• 2.4 DATA TRIANGULATION & MARKET BREAKDOWN
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 STUDY ASSUMPTIONS
• 2.7 ASSUMPTIONS/MARKET FORECASTING METHODOLOGY
• 2.8 LIMITATIONS AND RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET OVERVIEW
• 4.2 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
• 4.3 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION AND END USER, 2023 (USD MILLION)
• 4.4 GEOGRAPHIC GROWTH OPPORTUNITIES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising antimicrobial resistance
    • 5.2.1.2 Advancements in diagnostic technologies
    • 5.2.1.3 Expansion of clinical research applications
    • 5.2.1.4 Rise in government initiatives
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of automated instruments
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Emergence of rapid testing solutions
    • 5.2.3.2 Integration with digital health technologies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Intricate regulatory landscape
• 5.3 INDUSTRY TRENDS
  • 5.3.1 ISOTHERMAL MICROCALORIMETRY
  • 5.3.2 FLUORESCENCE-ACTIVATED CELL SORTING
  • 5.3.3 SMARTPHONE-BASED OPTICAL SPECTROSCOPY
  • 5.3.4 MICROFLUIDICS AND MICRODROPLETS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
  • 5.5.1 PROMINENT COMPANIES
  • 5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
  • 5.5.3 END USERS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 BARGAINING POWER OF SUPPLIERS
  • 5.7.3 BARGAINING POWER OF BUYERS
  • 5.7.4 THREAT OF SUBSTITUTES
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.8.2 BUYING CRITERIA
• 5.9 PATENT ANALYSIS
• 5.10 TRADE ANALYSIS
  • 5.10.1 IMPORT DATA
  • 5.10.2 EXPORT DATA
• 5.11 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.13 TECHNOLOGY ANALYSIS
  • 5.13.1 KEY TECHNOLOGIES
    • 5.13.1.1 PCR
    • 5.13.1.2 Microfluidics and lab-on-a-chip
    • 5.13.1.3 Synthetic antimicrobial peptides
  • 5.13.2 COMPLIMENTARY TECHNOLOGIES
    • 5.13.2.1 MALDI-TOF
  • 5.13.3 ADJACENT TECHNOLOGIES
    • 5.13.3.1 Nanotechnology
    • 5.13.3.2 Nanomotion technology
    • 5.13.3.3 Biochip technology
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 NORTH AMERICA
    • 5.14.1.1 US
    • 5.14.1.2 Canada
  • 5.14.2 EUROPE
  • 5.14.3 ASIA PACIFIC
    • 5.14.3.1 Japan
    • 5.14.3.2 China
    • 5.14.3.3 India
  • 5.14.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.15 INVESTMENT AND FUNDING SCENARIO
• 5.16 PRICING ANALYSIS
  • 5.16.1 AVERAGE SELLING PRICE, BY REGION
  • 5.16.2 AVERAGE SELLING PRICE, BY KEY PLAYER
• 5.17 REIMBURSEMENT SCENARIO
• 5.18 UNMET NEEDS AND KEY PAIN POINTS
• 5.19 IMPACT OF AI/GEN AI ON ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET

6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 CULTURE & GROWTH MEDIA
    • 6.2.1.1 High utilization of disk diffusion and broth dilution methods to drive market
  • 6.2.2 SUSCEPTIBILITY TESTING DISKS
    • 6.2.2.1 Low costs, ease of use to support adoption
  • 6.2.3 MIC STRIPS
    • 6.2.3.1 Accuracy, simplicity, and thorough results to drive usage
  • 6.2.4 SUSCEPTIBILITY TESTING PLATES
    • 6.2.4.1 Availability of specialized plates to drive market
• 6.3 LAB INSTRUMENTS
  • 6.3.1 AUTOMATED LABORATORY INSTRUMENTS
    • 6.3.1.1 Ongoing trend of laboratory automation to fuel segment growth
  • 6.3.2 MOLECULAR DIAGNOSTICS SYSTEMS
    • 6.3.2.1 Technological advancements in molecular diagnostics to propel market
• 6.4 LAB DISPOSABLES
  • 6.4.1 INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED IN HOSPITALS TO DRIVE DEMAND

7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 ANTIBACTERIAL SUSCEPTIBILITY TESTING
  • 7.2.1 EMERGENCE OF MULTIDRUG-RESISTANCE TO INCREASE ADOPTION OF ANTIBACTERIAL SUSCEPTIBILITY TESTING PRODUCTS
• 7.3 ANTIFUNGAL SUSCEPTIBILITY TESTING
  • 7.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO PROPEL DEMAND FOR TESTING
• 7.4 ANTIPARASITIC SUSCEPTIBILITY TESTING
  • 7.4.1 RISING AWARENESS TO SUPPORT MARKET GROWTH
• 7.5 ANTIVIRAL SUSCEPTIBILITY TESTING
  • 7.5.1 ADVANCEMENTS IN ANTIVIRAL SUSCEPTIBILITY TESTING TO ENHANCE PATIENT OUTCOMES

8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD

• 8.1 INTRODUCTION
• 8.2 QUALITATIVE METHODS
  • 8.2.1 AUTOMATED AST
    • 8.2.1.1 Advancements and resistance patterns to drive use of automated instruments
  • 8.2.2 DISK DIFFUSION
    • 8.2.2.1 Simplicity, accuracy, and flexibility to support adoption
  • 8.2.3 AGAR DILUTION
    • 8.2.3.1 Time-consuming and labor-intensive nature to affect adoption
  • 8.2.4 GENOTYPIC METHOD
    • 8.2.4.1 Gold standard status to support greater adoption
• 8.3 QUANTITATIVE METHODS
  • 8.3.1 ETEST METHOD
    • 8.3.1.1 Etest to hold larger share of quantitative methods market
  • 8.3.2 BROTH MACRODILUTION
    • 8.3.2.1 Precision, simultaneous testing capability to drive market

9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 CLINICAL DIAGNOSTICS
  • 9.2.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
• 9.3 DRUG DISCOVERY & DEVELOPMENT
  • 9.3.1 EMPHASIS ON R&D AND INNOVATION TO SUPPORT DEMAND GROWTH
• 9.4 EPIDEMIOLOGY
  • 9.4.1 NEED FOR BETTER UNDERSTANDING AND DECISION MAKING TO PROPEL ADOPTION
• 9.5 OTHER APPLICATIONS

10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS & DIAGNOSTIC CENTERS
  • 10.2.1 HOSPITALS & DIAGNOSTIC CENTERS TO HOLD LARGEST MARKET SHARE
• 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.3.1 EMPHASIS ON PRODUCT DEVELOPMENT TO DRIVE MARKET
• 10.4 ACADEMIC & RESEARCH INSTITUTES
  • 10.4.1 RISING R&D ACTIVITY AND SUPPORT FOR RESEARCH TO DRIVE MARKET
• 10.5 CLINICAL RESEARCH ORGANIZATIONS
  • 10.5.1 EXPANSION OF CLINICAL TRIALS WORLDWIDE TO PROPEL MARKET GROWTH

11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 11.2.2 US
    • 11.2.2.1 US to hold largest share of North American market
  • 11.2.3 CANADA
    • 11.2.3.1 Favorable government initiatives to drive market growth
• 11.3 EUROPE
  • 11.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 11.3.2 GERMANY
    • 11.3.2.1 Government initiatives for AMR to drive market
  • 11.3.3 FRANCE
    • 11.3.3.1 Focus on enhancing AMR surveillance to propel market
  • 11.3.4 UK
    • 11.3.4.1 New action plans for AMR to propel adoption
  • 11.3.5 ITALY
    • 11.3.5.1 Rising instances of AMR and high use of antibiotics to propel demand for testing
  • 11.3.6 SPAIN
    • 11.3.6.1 Rising AMR in gram-negative bacilli to drive market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 11.4.2 JAPAN
    • 11.4.2.1 Industry-government collaborations for infectious disease management to support market growth
  • 11.4.3 CHINA
    • 11.4.3.1 Rising emphasis on AMR management to drive market
  • 11.4.4 INDIA
    • 11.4.4.1 Expanding government and industry efforts in clinical diagnostics to propel market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Establishment and implementation of antimicrobial treatment guidelines to favor market growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Need for rapid AMR detection to drive demand for automated AST systems
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 11.5.2 BRAZIL
    • 11.5.2.1 Rising emphasis on implementing AMR detection to drive market
  • 11.5.3 MEXICO
    • 11.5.3.1 Economic growth to support expansion of AST systems
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Healthcare infrastructural development initiatives to support growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
• 12.3 REVENUE ANALYSIS
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product footprint
    • 12.5.5.4 Type footprint
    • 12.5.5.5 Method footprint
    • 12.5.5.6 Application footprint
    • 12.5.5.7 End-user footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES & APPROVALS
  • 12.9.2 DEALS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 BIOMERIEUX SA
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches & approvals
      • 13.1.1.3.2 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 BECTON, DICKINSON AND COMPANY
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
      • 13.1.2.3.2 Other developments
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 THERMO FISHER SCIENTIFIC INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches & approvals
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 DANAHER CORPORATION
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches & approvals
      • 13.1.4.3.2 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 BIO-RAD LABORATORIES, INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
      • 13.1.5.2.1 Deals
    • 13.1.5.3 MnM view
      • 13.1.5.3.1 Right to win
      • 13.1.5.3.2 Strategic choices
      • 13.1.5.3.3 Weaknesses and competitive threats
  • 13.1.6 BRUKER
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches & approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 ROCHE DIAGNOSTICS
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches & approvals
      • 13.1.7.3.2 Deals
  • 13.1.8 MERCK KGAA
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Deals
  • 13.1.9 ACCELERATE DIAGNOSTICS, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches & approvals
      • 13.1.9.3.2 Deals
      • 13.1.9.3.3 Other developments
  • 13.1.10 HIMEDIA LABORATORIES
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
  • 13.1.11 LIOFILCHEM S.R.L.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
  • 13.1.12 ALIFAX S.R.L.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
  • 13.1.13 CREATIVE DIAGNOSTICS
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
  • 13.1.14 SYNBIOSIS
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
  • 13.1.15 BIOANALYSE
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
• 13.2 OTHER KEY PLAYERS
  • 13.2.1 ZHUHAI DL BIOTECH CO., LTD.
  • 13.2.2 ELITECHGROUP
  • 13.2.3 MAST GROUP LTD.
  • 13.2.4 CONDALAB
  • 13.2.5 GENEFLUIDICS, INC.
  • 13.2.6 BIOTRON HEALTHCARE
  • 13.2.7 INVIVOGEN
  • 13.2.8 MP BIOMEDICALS
  • 13.2.9 QUANTAMATRIX INC.
  • 13.2.10 SYSMEX EUROPE SE
  • 13.2.11 COPAN DIAGNOSTICS INC.
  • 13.2.12 ERBA DIAGNOSTICS MANNHEIM GMBH

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS